A Randomized, Blinded, Placebo-Controlled Dose-Ranging Phase 1b Study of the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects with Chronic Hepatitis B Virus Infection

2024-511051-18-00 Protocol ABI-4334-102 Human pharmacology (Phase I) - Other Ended

End 14 May 2025 · Status Ended · 2 EU/EEA countries · 3 sites · Protocol ABI-4334-102

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 50
Countries 2
Sites 3

chronic hepatitis B virus infection (cHBV)

Key facts

Sponsor
Assembly Biosciences Inc.
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Virus Diseases [C02]
Trial duration
completed 14 May 2025
Decision date (initial)
2024-07-30
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

chronic hepatitis B virus infection (cHBV)

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Assembly Biosciences Inc.

Sponsor organisation
Assembly Biosciences Inc.
Address
2 Tower Place
City
South San Francisco
Postcode
94080-1826
Country
United States

Scientific contact point

Organisation
Assembly Biosciences Inc.
Contact name
Chief Medical Officer

Public contact point

Organisation
Assembly Biosciences Inc.
Contact name
Chief Medical Officer

Locations

2 EU/EEA countries · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ended 7 1
Romania Ended 15 2
Rest of world
Moldova, Republic of, New Zealand
28

Investigational sites

Bulgaria

1 site · Ended
Multiprofile Hospital for Active Treatment Sveta Sofia
Gastroenterology, Bulevard Bilgariya 104, 1404, Sofiya

Romania

2 sites · Ended
Institutul National De Boli Infectioase Prof.Dr.Matei Bals
Pavilion 1, wards: 2, 3, 4, 5, Strada Dr. Calistrat Grozovici Nr. 1, 021105, Bucharest
Spitalul Clinic Judetean De Urgenta Cluj
Ophthalmology Building, 1st floor, wards: 33, 34, 35, Strada Clinicilor 3-5, 400006, Cluj-Napoca

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-23 Romania Acceptable with conditions
2024-07-29
2024-07-30
2 SUBSTANTIAL MODIFICATION SM-1 2024-08-16 Romania Acceptable
2024-09-23
2024-09-25